COMPARISON OF NEW ANTIALLERGIC EYE DROPS, LEVOCABASTINE VERSUS NAAGA,BY THE CONJUNCTIVAL CHALLENGE TEST

In order to evaluate the efficacy and tolerability of an antihistamine in the form of eye drops, 0.05% levocabastine, a randomised, double-b lind trial versus NAAGA (N-acetyl-aspartyl-glutamic acid) was undertak en in 22 subjects with grass pollen allergy, in the prevention of symp tomatology induced by a conjunctival challenge test (CCT). Patients re ceived a single instillation of levocabastine in one eye and of NAAGA in the other eye, in accordance with predetermined randomisation, 15 m inutes before the CCT. This instillation was followed by a challenge t est using the threshold allergen concentration determined in a selecti on challenge test. The efficacy of levocabastine was evaluated by the decrease in intensity of the allergic reaction (association of hyperem ia and pruritus) in comparison with NAAGA, 5 minutes after the challen ge test. Efficacy results revealed a statistically significant reducti on (p < 0.0001) in allergic response in the group treated with levocab astine as compared with NAAGA. Local tolerability was satisfactory and similar with both types of eye drops.